glp 1 for kidney disease GLP-1 agonists in the treatment of chronic in type 2 diabetes and obesity GLP-1 Receptor Agonists and Kidney

F.Marques TavaresB.VillelaE

Albiglutide Harmony outcomes was a double-blind trial that included a total of 9,463 T2D participants of 40 years of age and a history of CVD, who were allocated to an albiglutide (3050 mg weekly) group or placebo group ( Renoprotection of GLP-1RAs is Largely Dependent on Reduction of Albuminuria As described above, GLP-1RAs have no clinically important effect on eGFR and hard renal endpoints

8 ChristouH.ConnorsJ

10.3390/nu16020182 66 CassaniE.PriviteraG.PezzoliG.PusaniC.MadioC.IorioL.et al

Research on CJC-1295 has investigated its capacity to sustain elevated GH-releasing activity in pre-clinical models, while Ipamorelin studies have focused on its selectivity it appears to stimulate GH release with less impact on cortisol and prolactin than earlier-generation GHRPs

Heavy Metals: 10 ppm max